Phase I Study: Zanzalintinib with Pembrolizumab and Cetuximab in Recurrent/Metastatic HNSCC

University of Chicago is evaluating the safety, tolerability, and optimal dosing of zanzalintinib—a dual cMet and VEGFR inhibitor—in combination with cetuximab and pembrolizumab in a Phase I dose-escalation/expansion trial for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study will determine the maximally tolerated dose and assess preliminary efficacy outcomes, including progression-free and overall survival, over 42-day treatment cycles.